Merck invests $50m in Personalis to bolster Moderna collaboration on individualized cancer therapies
Personalis, Inc., a leader in precision oncology solutions, has secured a significant investment from Merck and extended its partnership with Moderna. These strategic agreements aim ... Read More
Merck’s WELIREG receives positive CHMP opinion for VHL tumours and advanced RCC
Merck, known as MSD outside the U.S. and Canada, has moved a step closer to offering innovative treatment options in Europe. The European Medicines Agency’s ... Read More
Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines
In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as MSD outside the U.S. and Canada, has ... Read More
Merck’s $1.3bn bet on cancer therapy: Inside the Modifi Biosciences acquisition
Merck & Co., a global leader in pharmaceuticals, has acquired Modifi Biosciences, a cutting-edge biotech startup based in New Haven, Connecticut, for up to $1.3 ... Read More
Breakthrough liver cancer treatment: Merck’s new drug combo slashes disease progression risk by 34%
Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have announced encouraging results from the first interim ... Read More
Health Canada approves KEYTRUDA and Enfortumab Vedotin for advanced urothelial cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination ... Read More
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an ... Read More
Merck to acquire EyeBio in $3bn deal to expand ophthalmology pipeline
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced a definitive agreement to acquire EyeBio Limited, a prominent ... Read More
Merck announces over €300m investment in new bioprocessing center in South Korea
Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a new Bioprocessing Production Center located in Daejeon, ... Read More
Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial
Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, ... Read More